

Conquer Cancer through AI



Company Overview

About Lunit



Since 2013
1st Generation Medical AI Company



1st Ranked

Voted as No.1 most anticipated IPO in 2022 (Korea)

더벨 2022.03.04.

[바이오마켓 트렌드]투자자들이 꼽은 올해 IPO 최고 기대주 '루닛'

국내 바이오 투자자들이 꼽은 올해 IPO 기대주는 디지털 헬스케어 업체 루닛이었다. 작년 기술성 평가에서 최고 등급(AA-AA)을 받았고 글로벌 사업 성과가 나오는 점 등이 두루 작용했다. 작년 5000억원이 넘는...

AA-AA

Unprecedented "AA-AA" highest level in technology assessment

바이오스캐터 2021.05.14.

루닛, 기평통과 AA, AA "역대 최고"..하반기 예심청구

루닛에 따르면 지금까지 헬스케어 기업 중 AA, AA 등급을 받은 기업은 루닛이 최초다. 루닛은 한국거래소가 지정한 두 곳의 전문기술평가기관인 한국기업데이터와 이크레더블에서 모두 A...

VC

First Korean medical device company funded by major US healthcare VC



HEALTHQUEST PICKS KOREA'S LUNIT FOR FIRST INVESTMENT IN ASIA

HealthQuest Capital, a major US healthcare-focused venture growth fund, made its first investment in Asia along with other venture capitalists by purchasing shares in Lunit Inc., South Korea's startup developing cancer detection solutions based on artificial intelligence (AI). HealthQuest invested \$20M in the round.

GE

First AI company chosen by GE Healthcare for collaboration in chest x-ray business



<https://www.fiercebiotech.com/medtech/ge-healthca...>

GE Healthcare rolls out new AI-powered chest X-ray suite

2020. 6. 19. — GE Healthcare launched an artificial intelligence-powered chest X-ray analysis suite designed to spot and highlight eight common conditions ...

Guardant

Guardant Health's first strategic investment ever



Lunit receives \$26M funding from Guardant Health
By AuntMinnie.com staff writers

July 19, 2021 — South Korean artificial intelligence (AI) software developer Lunit recently announced a strategic investment of \$26 million from Guardant Health. The deal includes a collaboration intended to develop AI tools for pathology image

5-7x

Revenue growth during early commercialization (2019~2021)

연방뉴스 임력 2022.05.16, 오전 11:10

루닛, Q1 매출 29억7천6백만원...전년 동기 대비 552% 성장

(저널=연방뉴스) 김찬디 기자 = 의료 인공지능(AI) 기업 루닛은 올해 1분기 연속 기존 매출액이 29억7천6백만원으로 지난해 같은 기간보다 552% 성장했다고 16일 밝혔다.

- '19~'20 revenue ↑7x
- '20~'21 revenue ↑5x
- '21 1Q~'22 1Q revenue ↑5x

Core Competence

#1 Technology



Strong Foundation

Tech-based startup

- Six co-founders from KAIST
- First deep learning startup in Korea
- Top-tier AI researchers

KAIST

AI Researchers

44 14%

Software Developers

72 24%



Anthony Paek
Chairman



Sunggyun Park
INSIGHT
Chief Product Officer



Kyunghyun Paeng
SCOPE
Chief Product Officer



Donggeun Yoo
Chief of AI
Research



Minhong Jang
INSIGHT
Chief Business Officer



Jeongin Lee
VP of IT &
Infrastructure



Top Class A.I

Global leader in AI tech

- Top-tier researchers gather at Lunit
- Rich medical data available for algorithm training
- Ranked top places in international competitions

Presentations in Top AI Conferences

+30



Top Rank in AI Competitions

2015

Main Task
(CLS-LOC)

IMAGENET

1	Microsoft
5	Lunit
7	Google

2016

MICCAI Grand
Challenge

Tumor Proliferation
Assessment

1	Lunit
2	IBM
3	Microsoft

2017

Camelyon

CAMELYON17

1	Lunit
2	Harvard Univ.
3	Eindhoven Univ. of Tech



Global Recognition

International spotlight

- The **only Korean company** spotlighted by World Economic Forum, CB Insights



2017

CB Insights
AI 100



2022

World Economic Forum
GLOBAL INNOVATOR



2019 / 2020 / 2021

CB Insights
DIGITAL HEALTH 150

Forbes

Newsweek

BBC

FIERCE
Biotech

MIT
Technology
Review

Core Competence

#2 Medical Expertise

CEO Profile



Brandon Suh MD, MBA,

MPH
Chief Executive Officer

- Board-Certified Physician in Family Medicine
- M.D., Seoul National University
- M.P.H. in Public Health, Yonsei University
- M.B.A., Kyunghee University
- B.A. in Biological Science, KAIST

12 Full-time Physicians at Lunit



Brandon Suh
Family Medicine



Kihwan Kim
Radiology



Chanyoung Ock
Oncology



HyungKook Yang
Family Medicine



Sanghyup Lee
Radiology



Yoojoo Lim
Oncology



Sooick Cho
Dermatology



Eunkyung Park
Radiology



Ambika Seth
Radiology



Wonkyung Jung
Pathology



Seunghwan Shin
Rheumatology



John Jongseok Ahn
General Physician

Renowned Scholars as Advisors



Eliot Siegel
Radiologist
Radiology IT
KOL



Tony Mok
Oncologist
Board member
of AstraZeneca



Linda Moy
Breast Radiologist
KOL,
RSNA Vice-chair



YoungKwang Chae
Oncologist
KOL in
immunotherapy



Yung-jue Bang
Oncologist
KOL in Korea

+160 Publications in major peer-reviewed journals



+80 Research Partnerships



Core Competence

#3 Global Business

Global Talents at Lunit



Ken Nesmith
 Founder of Lexent Bio (acquired by Foundation Medicine)
 MIT, Wharton School



Marcus Skovhus
 Head of Corporate Strategy at Roche and Foundation Medicine



Thijs Kooi
 Published AI research papers in top AI journals



Sergio Pereira
 Leading AI researcher in medical imaging (MRI)



Wei-cheng Wang
 Software Development lead at Yahoo and Foxconn



Ambika Seth
 Radiologist, Clinical research for AI startups

International Colleagues
 (non-Koreans)

40 15%

Global Investors Back Lunit

- **95b KRW** funded by overseas investors (60% of total funding)
- First Korean medical device company invested by major US Healthcare VCs (Pre-IPO funding round)
- Multiple Strategic Investments by industry leaders



International Shareholders

Lunit	23%
CELLTRION	20%
SAMSUNG BIOLOGICS	10%
KOSDAQ Listed Medical AI companies Syntelabio, Inc. VUNO nouL JLK INSPECTION LifeSemantics [DEEPNOID]	< 2%

Global Sales Channel through Strong Business Partnerships




80% US Oncologists using Guardant Health products

Global Big Pharma

Currently discussing research/collaboration agreement with multiple big pharmas

Conquer Cancer through AI | Increase survival with AI-based cancer diagnosis and treatment



1
Cancer diagnostics solutions

2
Cancer treatment support solutions

Lunit INSIGHT®

+50%
50% more patients can be screened earlier

Chest X-Ray Mammography
Chest CT 3D Mammo (DBT)

Lunit SCOPE®

+50%
50% more patients can be eligible for immunotherapy

CT / MRI Tissue
DNA / RNA



THANK YOU